January 2, 2016

Next Generation Sequencing (NGS) Diagnostics Company

Next Generation Sequencing (NGS) Diagnostics Company


NGS diagnostics

  • Next generation sequencing can identify target genes in only 20%-40% patients who can benefit from targeted cancer drugs.
  • Normally, other 60%-80% of cancer patients would not be able to benefit from the sequencing results in finding personalized cancer drug treatment.

NGS diagnostics + GIFTS analysis

  • By combining NGS results with GIFTS analysis, most of those remaining 60%-80% of patients will also be able to find treatments.

CHINA: 590 RuiQing Road, Building 7, 5F Zhangjiang Hi-Tech Park (East), 201201, Shanghai
US: 1455 Adams Drive, Menlo Park CA 94025